The AI landscape doesn't move in one direction — it lurches. Some techniques leap from experiment to table stakes in a single quarter; others stall against regulatory walls, technical ceilings, or organisational inertia that no amount of hype can dislodge. Knowing which is which is the hard part. The State of Play cuts through the noise with a rigorously maintained index of AI techniques across every major business domain — classified by maturity, evidenced by real-world adoption, and updated daily so you always know where you stand relative to the field. Stop guessing. Start knowing.
A daily newsletter distilling the past two weeks of movement in a domain or two — delivered to your inbox while the index updates in the background.
Each dot marks the weighted maturity of practices within a domain — hover for a brief summary, click for more detail
AI that continuously monitors sources for new information on defined topics and alerts users to significant developments. Includes automated literature watch and competitive signal monitoring; distinct from deep research which conducts one-off investigations rather than ongoing surveillance.
Continuous research monitoring and alerting has transitioned from second-wave pilots into standardised operational practice across pharma, healthcare, and enterprise contexts. The ecosystem shows clear signs of maturation: major platforms (DistillerSR, Sorcero, Nested Knowledge, MadeAi) have moved past experimental deployments to governance-focused standardisation, regulatory authorities (FDA) have operationalised automated signal detection, and case studies document substantial productivity gains (50-95% reduction in manual labour, 98% faster screening cycles). Yet the transition remains incomplete and uneven. Alert fatigue and threshold-tuning overhead continue to dominate deployment friction; most organisations still lack the operational discipline to sustain continuous monitoring at scale. The technology is proven. The limiting factor is not capability but organisational willingness to invest in the governance, training, and workflow redesign required to make alerts valuable rather than noisy.
Ecosystem maturity is advancing rapidly across pharma, regulatory affairs, medical device, and financial services with accelerating market scaling. Market analysis shows >90% of big pharma now using digital systems for automated adverse event reporting, with the pharmacovigilance automation market projected to grow from $2.80B (2025) to $5.25B (2035, 6.5% CAGR)—lower projections than earlier estimates but reflecting consolidation around established vendors. Pharmavigilance deployments define the maturity curve: DistillerSR operates at significant scale with 250+ customers (80% of top pharma and medical device companies) delivering 70% screening time reductions. Sorcero's $42.5M Series B, one-third of top-30 global pharma customer base, and Medical Affairs suite expansion (including the new Therapy Resonance Profile for real-time continuous monitoring and stakeholder sentiment tracking) confirm sustained enterprise momentum. Regulatory intelligence platforms mature: Flinn.ai (100+ MedTech manufacturers) continuously monitors 120+ jurisdictions with AI-driven impact assessment; Qoniq case study documents EU IVDR-compliant automation reducing weekly manual burden from 25-30 hours to automated cadence. Real-world pharmacovigilance deployments show proactive signal detection: STAR Systems AINE ingests MedWatch, AERS, and literature feeds to flag safety signals months earlier than manual processes, with CFR 21 Part 11 compliant audit trails for regulatory inspection readiness. CoVigilAI covers 154+ countries; systems screen 2.5M+ articles annually with 99% adverse event capture. FDA's CBER expanded post-market surveillance to 24+ protocols across COVID-19, RSV, influenza, and mpox vaccines with active monitoring master frameworks integrating Medicare claims, EHRs, and immunization registries; FDA's Elsa tool and MOSAIC-NLP programme operational. Healthcare validation: Houston Methodist's 8-hospital rollout achieved 95% device use and 4-hour shift time savings; Cleveland Clinic's COSMOS study optimised threshold tuning to 1 alarm per 8 hours. Academic deployments expanding — Oncoscope-AI automates oncology monitoring of 3,898 studies with 98.6% faster daily cycles. Medical writing consolidating around continuous platforms (CiteMed, BiomchBERT). Emerging evolution: Capgemini and other consultancies position agentic AI as the next phase, with autonomous systems managing signal detection, real-time insight generation, and multi-workflow orchestration; vendor implementations (Microsoft Copilot with Part 11 audit trail governance) begin staged rollouts with targeted ROI (6-12 month payback at mid-market scale).
Governance and regulatory validation now define maturity inflection. ISPOR 2026's "Beyond the Bots" panel (DistillerSR, Nested Knowledge, MadeAi) signals transition to second-phase standardisation: reproducibility, auditability, version control, and governance frameworks. European Medicines Agency's 2025 AI Observatory Report recognises continuous monitoring for signal detection, social media surveillance, and automated ICSR processing as mainstream practice, identifying priorities: explainability, model validation, and governance infrastructure. UK MHRA's June 2026 regulatory sandbox tests AI for continuous safety assessment and risk prediction, signalling government-level validation of continuous monitoring at governance tier. Professional maturity codified: Whitehall Training's certification course (97% adoption rate, 536 reviews) covers automated case triage and signal detection, indicating practitioner-ready tooling and standardised operational patterns.
Regulatory frameworks enabling financial services expansion: FDA's January 2025 guidance (final Q2 2026) provided first comprehensive AI framework across drug lifecycle including post-marketing safety; EMA's late 2024 Reflection Paper operationalised via EMA tools for automated signal adjudication and literature screening; CIOMS Working Group XIV December 2025 report established first internationally aligned framework with seven governing principles (risk-proportionate oversight, human accountability, lifecycle governance). EU's Anti-Money Laundering Authority (AMLA) June 2026 guidelines mandate continuous customer/transaction monitoring and explicitly permit advanced analytical tools (including AI) with effective human oversight—mandated across all 27 EU Member States starting July 2027, driving regulatory-mandated adoption in financial services. Domain expansion accelerates: venture capital continuous startup scouting (Lyzr AI) achieves 70% faster identification and 40% deal flow improvement; financial services regulatory compliance platforms (Vixio monitors 8,000+ regulatory authorities across ~200 jurisdictions with configurable alerting; FINTRAC and JPMorgan Chase implementing AI for real-time compliance monitoring) advancing continuous surveillance at scale; intelligence applications show 5-layer OSINT monitoring systems detecting geopolitical weak signals. Commercial continuous monitoring platforms now standard: Fullintel serves Top 100 pharma with 24/7 analyst review across 300,000+ sources and 50% cost reduction; market-wide adoption signals 40% of insights leaders continuously review CI using monitoring tools. Pharmacovigilance signal detection market specifically growing to USD 6.8B by 2035 (12.5% CAGR), outpacing overall market growth.
Adoption remains unevenly distributed and governance barriers intensify at scale. Alert fatigue and threshold-tuning overhead dominate friction outside pharma/healthcare/regulatory. A 2025 telemonitoring study showed 5-10 mmHg adjustments halve manual processing; simultaneously, 73% of organisations experience outages from ignored alerts, 59% report excessive volume, and 40% of alerts are never investigated. Alert system design analysis reveals five systemic failures: diagnostic context absent, severity tiering missing, ownership undefined, response protocols absent, static thresholds. Scaling barriers now documented empirically: 60% of pharma/biotech AI pilots fail to reach production deployment (2025 survey, 115 executives); data quality and governance neglect identified as primary cause—orgs with successful scaling invest 4x more in foundational governance infrastructure vs. poor performers. The binding constraint remains organisational: technology capability is proven at scale and regulatory frameworks now enable deployment, but sustained governance discipline, alert calibration, human-in-the-loop oversight, and data quality infrastructure are absent in most organisations outside regulated pharma and healthcare. Platforms expand into new domains (buyer-intent, competitive signals, congress monitoring, venture monitoring, regulatory change) but each reveals the same pattern—threshold tuning and signal-to-noise filtering demand organisational discipline and governance maturity most teams lack.
— Independent news coverage: Parexel chief AI officer reports AI underutilization in real-time clinical trial data review, adaptive monitoring, and safety signal detection; structural barriers (validation, governance, inspector assessment) are primary adoption constraints, not technology capability.
— Vendor assessment validating AI for regulatory-intelligence monitoring (tracking agency updates across jurisdictions) while cautioning against over-reliance; documents need for AI-specific SOPs, expert review, and task-appropriate human oversight models.
— UPenn institutional deployment: continuous LLM monitoring of 400,000+ Reddit posts detecting underreported adverse effects (menstrual irregularities, chills, hot flashes, fatigue). Demonstrates speed and value of continuous social media surveillance.
— Practitioner analysis and solution: Epic Sepsis Model failure (109 false alerts per true case); TREWS multi-hospital outcomes study (Nature Medicine, 590,736 patients) demonstrates continuous monitoring approach minimizing false alarms.
— Industry analysis: agentic AI reclaiming up to 40% of pharmacovigilance capacity via autonomous multi-step workflows (2025–2026); centralized data lakes integrating internal + external regulatory data with NLP for concept and sentiment detection.
— FDA Sentinel Initiative integrating EHRs and Gen AI/ML for continuous national-scale post-marketing safety surveillance across millions of patient records; demonstrates government-scale deployment in most stringent regulatory environment.
— Peer-reviewed research on false alarm behavior in drift detectors (PSI, KS, MMD, LSDD) in production ML monitoring; Bonferroni correction tradeoff reduces false positives at cost of sensitivity—applicable to pharmacovigilance and safety monitoring.
— Deployed GA product for continuous literature monitoring across 2,200+ journals with instant email alerts and weekly reports; 50–70% time-savings vs. manual; customer testimonials confirm adoption in regulated pharmacovigilance.